RU2015140572A3 - - Google Patents

Download PDF

Info

Publication number
RU2015140572A3
RU2015140572A3 RU2015140572A RU2015140572A RU2015140572A3 RU 2015140572 A3 RU2015140572 A3 RU 2015140572A3 RU 2015140572 A RU2015140572 A RU 2015140572A RU 2015140572 A RU2015140572 A RU 2015140572A RU 2015140572 A3 RU2015140572 A3 RU 2015140572A3
Authority
RU
Russia
Application number
RU2015140572A
Other languages
Russian (ru)
Other versions
RU2015140572A (ru
RU2674147C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2015140572A publication Critical patent/RU2015140572A/ru
Publication of RU2015140572A3 publication Critical patent/RU2015140572A3/ru
Application granted granted Critical
Publication of RU2674147C2 publication Critical patent/RU2674147C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/312Phosphonates
    • C12N2310/3125Methylphosphonates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/334Modified C
    • C12N2310/33415-Methylcytosine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/341Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2015140572A 2013-03-15 2014-03-14 Способы лечения колоректального рака RU2674147C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361790488P 2013-03-15 2013-03-15
US61/790,488 2013-03-15
US201361847287P 2013-07-17 2013-07-17
US61/847,287 2013-07-17
PCT/EP2014/055195 WO2014140333A1 (en) 2013-03-15 2014-03-14 Methods of treating colorectal cancer

Publications (3)

Publication Number Publication Date
RU2015140572A RU2015140572A (ru) 2017-04-24
RU2015140572A3 true RU2015140572A3 (enExample) 2018-03-21
RU2674147C2 RU2674147C2 (ru) 2018-12-05

Family

ID=50390057

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015140572A RU2674147C2 (ru) 2013-03-15 2014-03-14 Способы лечения колоректального рака

Country Status (11)

Country Link
EP (1) EP2970419B8 (enExample)
JP (2) JP6502863B2 (enExample)
KR (1) KR102232623B1 (enExample)
CN (1) CN105008394B (enExample)
AU (1) AU2014229985B2 (enExample)
CA (1) CA2903597C (enExample)
ES (1) ES2673209T3 (enExample)
MX (1) MX363746B (enExample)
NZ (1) NZ711564A (enExample)
RU (1) RU2674147C2 (enExample)
WO (1) WO2014140333A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ES3034412T3 (en) 2008-11-13 2025-08-18 Nogra Pharma Ltd Antisense compositions and methods of making and using same
AU2012307336B2 (en) 2011-09-15 2017-08-24 Nogra Pharma Limited Methods for monitoring responsiveness to anti-SMAD7 therapy
US10081809B2 (en) 2012-04-18 2018-09-25 University Of Miami Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
JP2017515896A (ja) 2014-05-09 2017-06-15 ノグラ ファーマ リミテッド 炎症性腸疾患の処置の方法
US10337004B2 (en) 2014-10-17 2019-07-02 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
JP2018529726A (ja) * 2015-09-30 2018-10-11 セルジーン アルパイン インベストメント カンパニー Ii, エルエルシー Tlr調節因子及び使用方法
WO2017147276A1 (en) 2016-02-23 2017-08-31 Celgene Corporation Methods of treating intestinal fibrosis using smad7 inhibition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ITRM20030393A1 (it) * 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
US7402574B2 (en) * 2004-03-12 2008-07-22 Avi Biopharma, Inc. Antisense composition and method for treating cancer
US20080114287A1 (en) * 2006-11-14 2008-05-15 Kar Neng Lai Ultrasound Microbubble Mediated Genes Delivery System
ES3034412T3 (en) * 2008-11-13 2025-08-18 Nogra Pharma Ltd Antisense compositions and methods of making and using same
UA107562C2 (uk) * 2008-12-05 2015-01-26 Спосіб лікування псоріазу
AU2012307336B2 (en) * 2011-09-15 2017-08-24 Nogra Pharma Limited Methods for monitoring responsiveness to anti-SMAD7 therapy

Also Published As

Publication number Publication date
RU2015140572A (ru) 2017-04-24
WO2014140333A1 (en) 2014-09-18
KR102232623B1 (ko) 2021-03-26
EP2970419B8 (en) 2019-12-11
JP2016517401A (ja) 2016-06-16
CA2903597A1 (en) 2014-09-18
CN105008394A (zh) 2015-10-28
ES2673209T8 (es) 2020-02-12
JP6502863B2 (ja) 2019-04-17
MX2015013255A (es) 2015-12-15
EP2970419A1 (en) 2016-01-20
RU2674147C2 (ru) 2018-12-05
CN105008394B (zh) 2021-10-22
HK1219489A1 (en) 2017-04-07
KR20150131260A (ko) 2015-11-24
EP2970419B1 (en) 2018-05-09
AU2014229985B2 (en) 2018-12-13
AU2014229985A1 (en) 2015-09-10
JP2019026649A (ja) 2019-02-21
ES2673209T3 (es) 2018-06-20
CA2903597C (en) 2023-04-04
NZ711564A (en) 2020-04-24
MX363746B (es) 2019-04-01

Similar Documents

Publication Publication Date Title
AP2016009275A0 (enExample)
BR112016005356A2 (enExample)
BR112016008207A2 (enExample)
BR112015007533A2 (enExample)
BR102016010778A2 (enExample)
BR112014017733A2 (enExample)
BR112014017739A2 (enExample)
BR112014019326A2 (enExample)
BR112016005345A2 (enExample)
BR112014018516A2 (enExample)
BR112016008235A2 (enExample)
BR112014020341A2 (enExample)
BR112014017855A2 (enExample)
BR112014017765A2 (enExample)
BR112014017669A2 (enExample)
BR112016015015A2 (enExample)
BR112014021878A2 (enExample)
BR112016003247A2 (enExample)
BR112016013968A2 (enExample)
BR112014019204A2 (enExample)
BR112014018207A2 (enExample)
BR112015015948A2 (enExample)
BR112014017722A2 (enExample)
BR112014017653A2 (enExample)
BR112014018578A2 (enExample)

Legal Events

Date Code Title Description
TC4A Change in inventorship

Effective date: 20190529